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A C-terminal fragment of an endogenous rabbit liver inhibitor for calcium-activated neutral protease 
(CANP) was produced in Escherichia coli and its inhibitory activity was examined after purification. The 
truncated inhibitor (373 amino acid residues), which contains two internal repeat structures, inhibits 2 mol 
CANP whereas the native liver inhibitor (639 residues), containing four internal repeat structures, inhibits 
4 mol CANP. This supports the hypothesis that the repeating unit is the functional unit of inhibition. The 
results also indicate that post-translational modification of the inhibitor is not essential for inhibition. 
Ca2 +-activated neutral protease; Calpain; Proteinase inhibitor 
1. INTRODUCTION 
Calcium-activated neutral protease (CANP, cal- 
pain, EC 3.4.22.17), a non-lysosomal cysteine pro- 
tease, participates in various cellular functions 
mediated by Ca2+ [l-3]. Thus, an understanding 
of the regulation of its activity is very important 
for elucidating its biological role. The activity is 
regulated mainly by Ca2+ and an endogenous in- 
hibitor, CANP inhibitor [2,4-61. Recently, we 
deduced the complete amino acid sequence of the 
rabbit inhibitor from the cDNA base sequence as 
a step in the analysis of the mechanism of inhibi- 
tion of CANP [7]. The sequence contains four in- 
ternal repeats of about 140 residues each. Since 
CANP inhibitors from various sources inhibit 
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3-8 mol CANP [6], we assumed that the repeating 
unit is the functional unit of inhibition. To con- 
firm this hypothesis, a cDNA fragment encoding 
the C-terminal half of the inhibitor was expressed / 
in E. coli, and the inhibitory activity of the protein 
product was examined together with the activity of 
native liver inhibitor. 
2. MATERIALS AND METHODS 
2.1. Materials 
The following materials were obtained from the 
sources indicated: casein, Merck; isopropyl-,&D- 
thiogalactopyranoside (IPTG), Wako Pure Chem- 
icals; phenylmethanesulfonyl fluoride (PMSF), 
ampicillin and kallikrein, Sigma; TPCK-trypsin, 
Millipore; a-chymotrypsin, Worthington; pro- 
teinase V8 (Staphylococcus aureus), Miles 
Laboratories; papain and bromelain, Boehringer 
Mannheim; TSK-gel phenyl-SPW, Toyo-Soda. 
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Lysylendopeptidase was a gift from Dr T. Masaki, 
Ibaraki University. 
2.2. A’ssay of CANP and its inhibitor 
The proteolytic activities of low- and high- 
Ca2+-requiring CANPs @CANP and mCANP) 
were measured at 1OOpM and 5 mM CaC12, 
respectively, using casein as a substrate [8]. The 
assay of the inhibitor for CANP was carried out as 
in [5]. 
2.3. Preparation of CANP, CANP inhibitor, 
cathepsins B and H, and ingensin 
,&ANP and mCANP were purified from rabbit 
skeletal muscle (spect. act. 400 and 180 U/mg, 
respectively) [9]. An endogenous inhibitor for 
CANP was purified to homogeneity (fig.lB) from 
rabbit liver essentially as in [lo]. Cathepsins B and 
H were prepared from rat liver [l 11. Ingensin was 
prepared from rat liver as in [12]. 
2.4. Plasmid 
During the course of cDNA cloning of the 
CANP inhibitor [7], a clone hCJ5S was isolated 
which contained in XgtlO a 2 kb insert DNA for the 
3’-region of the inhibitor mRNA (3.8 kb). XCJSS 
was subcloned into the EcoRI site of the pUC8 vec- 
tor. A resulting plasmid pCJ5S was found to ex- 
press a fat-fused protein as judged by the DNA 
sequence (see fig.3). The produced protein was ex- 
pected to encode a fused protein of 373 amino acid 
residues composed of 6 amino acid residues from 
the 1acZ gene and polylinker, and the C-terminal 
half (367 residues) of the rabbit CANP inhibitor. 
2.5. Bacterial culture and induction of truncated 
CANP inhibitor 
Cells of E. coli K-12 HBlOl carrying pCJ5S 
were grown at 37’C to late-log phase in 500 ml of 
x-broth [13], and further grown in 1 1 M9 medium 
[13] containing 50 mg ampicillin for 2 h. Then, 
1 ml of 1 M IPTG was added (final concentration: 
1 mM), and the cells were incubated for 1.5 h with 
shaking. 
2.6. Other methods 
The DNA sequence was determined by the 
dideoxy chain termination method [14]. SDS- 
polyacrylamide gel electrophoresis (SDS-PAGE) 
was carried out as in [15]. The amino acid com- 
position and protein sequence were analyzed by a 
Hitachi 835 amino acid analyzer and an Applied 
Biosystems 470A protein sequencer, respectively. 
The concentration of protein was determined by 
amino acid analysis. 
3. RESULTS 
3.1. Purification of truncated CANP inhibitor 
expressed in E. coli 
Cells of E. coli K-12 HBlOl harboring pCJ5S 
expressed large amounts of a 40 kDa polypeptide 
when induced with IPTG. The expressed inhibitor 
was heat-stable, simplifying its purification. The 
truncated CANP inhibitor was purified from the 
cell lysates according to the method established for 
the 107 kDa inhibitor from human liver [lo]. 
Cultured cells (-2 g) were washed with water, and 
suspended in 20 ml Tris-HCI, pH 7.5, containing 
5 mM EDTA and 5 mM 2-mercaptoethanol (buf- 
fer A) supplemented with 10 mM PMSF. Cells 
were disrupted with a Branson sonifier, model 185. 
Cell debris was removed at 15 000 rpm in a Hitachi 
RPR-20 rotor at 0°C. To the supernatant fraction, 
obtained after heating the extract for 10 min in 
boiling water, was added solid NaCl to a final con- 
centration of 1 M. The sample was applied to a 
phenyl-Sepharose CL4B column (3 x 5 cm) pre- 
equilibrated with buffer A containing 1 M NaCl. 
The column was eluted with the same buffer, and 
the flow-through fraction was collected and dia- 
lyzed against buffer A. The dialyzed sample was 
adsorbed to a DE-52 column (1.8 x 30 cm), and 
eluted with a linear gradient of O-O.4 M NaCl in 
buffer A. The inhibitor fraction eluted at 0.1 M 
NaCl was made 10 mM with respect to HCl, and 
applied to a TSK-gel phenyl-5PW RP column 
(4.6 x 75 mm). The column was developed with a 
linear gradient of O-80% (v/v) acetonitrile in 
0.1% (v/v) trifluoroacetic acid, and the elution 
was monitored at 210 nm. The purified truncated 
inhibitor, which was eluted at 40% (v/v) 
acetonitrile, was dried in a Savant Speed Vat con- 
centrator, dissolved in 5 mM EDTA and 5 mM 
2-mercaptoethanol, and stored at - 20°C. 
The purified truncated inhibitor showed a single 
band with a molecular mass of 40 kDa on SDS- 
PAGE (fig.lA). More than 10 mg of the 
homogeneous protein was obtained from a 1 1 
culture. 
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Fig.1. SDS-PAGE of the purified inhibitors. (A) The 
truncated inhibitor; B, the liver inhibitor. The 
approximate molecular masses of marker proteins are 
indicated. 
3.2. N-terminal sequences of the truncated and 
liver CANP inhibitors 
The amino acid composition of the purified in- 
hibitor agreed with that deduced from the cDNA 
sequence (table 1). The N-terminal sequence 
analysis of the truncated inhibitor showed that the 
protein produced was a polypeptide fused to a hex- 
apeptide derived from the IacZ gene and polylinker 
(table 2) as expected from the DNA sequence. The 
seventh Gly residue of the truncated inhibitor pro- 
tein corresponded to Gly-352 in the translation 
product of the mRNA for the CANP inhibitor as 
judged from the amino acid sequence (table 2, see 
fig.3). Thus, the truncated inhibitor contained the 
C-terminal half (367 residues) of the CANP in- 
hibitor. 
The N-terminus of the liver CANP inhibitor was 
assigned to Glu-80 of the translation product from 
the protein sequence analysis (table 2). Thus, the 
liver inhibitor loses the N-terminal 79 residues dur- 
ing the maturation of the primary translation 
product. 
3.3. Inhibition of CANP by the purified inhibitors 
The purified truncated and liver inhibitors in- 
hibited the caseinolytic activity of mCANP. The 
activity of CANP decreased linearly with increas- 
ing amounts of the inhibitors. From the values of 
the extrapolated intercepts, 1 mol of th.e truncated 
and liver inhibitors inhibited 1.9 and 4.1 mol 
mCANP, respectively (fig.2). Similar stoichiome- 
tric inhibitions were observed for &ANP by both 
inhibitors (not shown). These inhibitors had no 
effect on other proteases examined: ingensin, 
cathepsins B and H, kallikrein, trypsin, a-chymo- 
Table 1 
Amino acid composition of the truncated inhibitor 
-- 
Amino acid Deduced value from Experimental 
cDNAa value 
(mol%) 
Residues mol% 
Asx 9.7 
(Asp) 35 9.4 
(Asn) 6 1.6 
Thr 21 5.6 3.8 
Ser 40 10.7 10.9 
Glx 14.7 
(GM 42 11.3 
(Gin) 13 3.5 
Pro 42 11.3 11.9 
GLY 14 3.8 5.8 
Ala 38 10.2 12.6 
CYs 2 0.5 b 
Val 11 2.9 3.1 
Met 4 1.1 1.3 
Ile 9 2.4 1.7 
Leu 28 7.5 8.1 
T yr 2 0.5 0.5 
Phe 3 0.8 1.8 
LYS 49 13.1 10.2 
His 3 0.8 0.6 
Arg 11 2.9 3.4 
Total 373 99.9 100.1 
a Value corresponding to residues 352-718 of the rabbit 
inhibitor [7] with an extension of the N-terminus by six 
residues (see fig.3) 
b Not determined 
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Table 2 
N-terminal sequence of the CANP inhibitors 
Cycle 
number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Phenylthiohydantoin-amino acid 
released (pmol) 
Truncated Liver 
inhibitor inhibitor 
Thr (33) Glu (72) 
Met (241) Lys (69) 
Ile (183) Thr (8) 
Thr (25) Ala (67) 
Asn (145) Ser (8) 
Ser (7) Arg (14) 
Gly (78) Ser (7) 
Lys (185) LYS (39) 
Pro (172) Glu (39) 
Leu (101) Pro (58) 
Leu (157) Val (35) 
Pro (140) _a 
a Not determined 
Proteins used for the Edman degradation were 15 pg 
(375 pmol) and 1Oag (90 pmol) of the truncated and 
liver inhibitors, respectively. Recoveries of phenylthio- 
hydantoin-Ser and -Thr were usually 5-10% and 20‘70, 
respectively. For sequence, see legend to fig.3 
‘y 
o- . -,, o n _1 
0 1 2 3 4 
Inhibitor-Added (PmOl) 
54 3 2 1 
CANP/lnhibitor (mollmol) 
Fig.2. Inhibition of the activity of CANP by the purified 
inhibitors. The caseinolytic activity of mCANP (0.5 pg; 
4.5 pmol) was measured in the presence of various 
amounts of the truncated inhibitor (0) or the liver 
inhibitor ( w). Molar ratios of mCANP/inhibitor are also 
indicated. The amounts of the inhibitors were estimated 
using the molecular masses of 40 and 68 kDa for the 
truncated and liver inhibitors, respectively (see fig.3). 
trypsin, bromelain, papain, lysylendopeptidase 
and proteinase V8. These results indicate that the 
truncated inhibitor containing the C-terminal half 
of the liver inhibitor is active and has the same 
specificity as the native inhibitor, though the max- 
imum number of CANP molecule inhibited differs 
on a molar basis. 
4. DISCUSSION 
Our previous study indicated that the primary 
translation product of the CANP inhibitor is com- 
posed of 718 amino acid residues and contains four 
repeating structural units, hypothetical functional 
units, as shown in fig.3 [7]. Takano et al. [16] have 
also proposed a similar hypothesis on the basis of 
the partial sequence of the porcine inhibitor. The 
isolated liver inhibitor (MI 110000 by SDS-PAGE) 
lacks the N-terminal 79 residues, but contains the 
four repeating units. The truncated inhibitor used 
in this study corresponds to the region consisting 
residues 352-718 and contains two repeats. 
We have now shown that the truncated in- 
hibitor, in which no post-translational modifica- 
tions should be present, has the same inhibitory 
activity as the native inhibitor. This indicates that 
post-translational modification of the inhibitor is 
not essential for inhibition, although such 
Fig.3. Schematic structure of the CANP inhibitor. Four 
internal repeats of about 140 amino acids each are 
indicated in Roman numerals. The N-terminal sequences 
of the truncated inhibitor and the liver inhibitor are 
shown by the one-letter abbreviations [7]. The first 6 
residues of the truncated inhibitor, TMITNS are derived 
from the 1ucZ and polylinker; (ATG)ACCATGATT 
ACGAATTCG. The initiating Met corresponding to 
ATG could not be detected in the final product. The 
sequence from Gly-7 was identical to that from Gly-352. 
The N-terminal sequence of the liver inhibitor was 
assigned to the sequence from residue 80 in the cDNA 
sequence of the inhibitor. 
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modification(s) does occur in the liver inhibitor, as 
evidenced by the fact that the M, estimated by 
SDS-PAGE (110000) is significantly larger than 
the value (68000) calculated from the amino acid 
sequence [7]. 
1 mol of the liver inhibitor, which has four inter- 
nal repeats, inhibits 4 mol CANP. 1 mol of its C- 
terminal fragment containing two internal repeats, 
inhibits 2 mol CANP. The fact that the number of 
CANP inhibited by these inhibitors corresponds to 
the number of repeating units in their sequences, 
strongly supports the hypothesis that the repeating 
structural unit corresponds to the functional unit 
of inhibition. Furthermore, we have recent 
evidence that the erythrocyte inhibitor (MI 70000), 
corresponding to the C-terminal three quarters 
(residues 290-718 of the translation product) of 
the liver inhibitor and containing three repeating 
units, inhibits 3 mol CANP (to be published 
elsewhere). Taken together, each of the four 
tandemly repeated structural units in the liver in- 
hibitor is active and expresses its activity in- 
dependently. Preliminary characterization of 
truncated fragments corresponding to each of the 
four domains is consistent with this prediction. 
The CANP inhibitors are degraded easily during 
purification [10,17]. Thus, inhibitors with M, 
values clearly smaller than 110000 have been 
reported [6]. These inhibitors, however, show 
similar inhibitory activities [ 17,18], supporting the 
assumption that the presumed multidomains for 
inhibition have similar and independent inhibitory 
activities. 
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